Evaluation of remission state in chronic myeloid leukemia patients after bone marrow transplantation using cytogenetic and molecular genetic approaches.
The remission state of 13 Philadelphia positive chronic myeloid leukemia patients was studied after bone marrow transplantation (BMT) by cytogenetic and Southern blot analysis of the breakpoint cluster region (BCR) gene. Eight of 13 patients showed neither clinical nor genetic evidence of residual disease. In two patients hematological relapse was confirmed by cytogenetic and molecular analysis. Evidence for residual leukemic cells in otherwise complete remission was obtained genetically in three patients. One of the latter cases revealed BCR rearrangement despite negative cytogenetic findings, while in another patient cytogenetic relapse was observed without demonstrable rearrangement within the major BCR. Our results may indicate that cytogenetic and molecular genetic methods complement rather than replace each other for the detection of residual CML cells after BMT.
Arnold
R
R
Department of Internal Medicine III, University of Ulm, FRG.
Bartram
C R
CR
Heinze
B
B
Carbonell
F
F
Wiesneth
M
M
Hertenstein
B
B
Schmeiser
T
T
Heit
W
W
Kubanek
B
B
Heimpel
H
H
D000293:Adolescent; D000328:Adult; D015139:Blotting, Southern; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D003582:Cytogenetics; D005260:Female; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D011995:Recombination, Genetic; D012074:Remission Induction; D014158:Transcription, Genetic
D009363:Neoplasm Proteins; D016044:Fusion Proteins, bcr-abl